Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 14/20 | 0.62 |
| ▸ | PI4K2B | Q8TCG2 | 14/20 | 0.62 |
| ▸ | PI4K2A | Q9BTU6 | 14/20 | 0.62 |
| ▸ | PI4KB | Q9UBF8 | 14/20 | 0.62 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | NSD2 | O96028 | 1/20 | 0.44 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8595785 | 0.74 | PI4KA (0.71) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL14920025 | 0.74 | IDO1 (0.44) | IDO1 | |
| SCHEMBL2966404 | 0.69 | CCR9 (0.58) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL16487121 | 0.68 | PI4KA (0.51) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL5146335 | 0.67 | PI4KA (1.00) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL3538512 | 0.67 | PI4KA (0.77) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL27624028 | 0.67 | PI4KA (0.44) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL21788552 | 0.66 | ADORA2A (0.76) | PI4KAPI4K2BPI4K2API4KBNSD2 | |
| SCHEMBL11564490 | 0.66 | PI4KA (0.58) | PI4KAPI4K2BPI4K2API4KBNSD2 | |
| SCHEMBL27422663 | 0.65 | PI4KA (0.64) | PI4KAPI4K2BPI4K2API4KBEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2773641-B1 | BIARYL ETHER SULFONAMIDES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2017-09-27 | — | — | EP | disclosed |
| EP-2773641-B1 | BIARYL ETHER SULFONAMIDES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2017-09-27 | — | — | EP | disclosed |
| US-9481677-B2 | Biaryl ether sulfonamides and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2016-11-01 | — | — | US | disclosed |
| US-9481677-B2 | Biaryl ether sulfonamides and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2016-11-01 | — | — | US | disclosed |
| US-9481677-B2 | Biaryl ether sulfonamides and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2016-11-01 | — | — | US | disclosed |
| US-9365578-B2 | — | — | 2016-06-14 | — | — | US | disclosed |
| US-9365578-B2 | — | — | 2016-06-14 | — | — | US | disclosed |
| US-9365578-B2 | — | — | 2016-06-14 | — | — | US | disclosed |
| CN-104093716-A | Biaryl ether sulfonamides and their use as therapeutic agents | XENON PHARMACEUTICALS INC | 2014-10-08 | — | — | CN | disclosed |
| US-20140256736-A1 | BIARYL ETHER SULFONAMIDES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2014-09-11 | — | — | US | disclosed |
| US-20140256736-A1 | BIARYL ETHER SULFONAMIDES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2014-09-11 | — | — | US | disclosed |
| US-20140256736-A1 | BIARYL ETHER SULFONAMIDES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2014-09-11 | — | — | US | disclosed |
| EP-2773641-A1 | BIARYL ETHER SULFONAMIDES AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2014-09-10 | — | — | EP | disclosed |
| WO-2013064984-A1 | BIARYL ETHER SULFONAMIDES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2013-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256736-A1 | BIARYL ETHER SULFONAMIDES AND THEIR USE AS THERAPEUTIC AGENTS | TRPV1, TRPV3, TRPV2 | PI4KA 2688/4885PI4K2B 3139/4885PI4K2A 2849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.